Identificación de anticuerpos neutralizantes y la frecuencia de eventos adversos a las vacunas en el personal de salud del Hospital General de Macas que recibió la primera dosis de refuerzo de la vacuna para COVID-19

Abstract

Background: The determination of neutralizing antibodies allows us to evaluate the persistence of protection from the booster dose of the vaccine, while identifying the frequency of adverse reactions can provide local data on safety. Objective: Identify the presence of Neutralizing Antibodies and the Frequency of Adverse Events to vaccines in health personnel at the Macas General Hospital who received the first booster dose of the COVID-19 vaccine. Methods: Descriptive cross-sectional research. 82 health professionals from the Macas General Hospital inoculated with the first booster dose of the AstraZeneca vaccine were included, in whom the presence of neutralizing antibodies against SARS-Cov-2 was identified and the frequency of the adverse reactions presented was determined. through the Vaccine Adverse Event Reporting System (VAERS). Results: The presence of neutralizing antibodies was identified in 98% of participants. 89% of participants reported adverse reactions to the vaccine, the most common local reactions were: pain and sensitivity at the vaccine site 62% and 35%; The main systemic reactions were: headache 34%, general malaise 24%, feeling of fever 23%, myalgia 22%. No significant differences were found when comparing sex, age group and the presence of side effects with the generation of neutralizing antibodies. As well as associating sex and age group with the presence of adverse reactions. Conclusion: The administration of the booster dose was associated with the presence of neutralizing antibodies nine months after inoculation; the adverse reactions identified were mild in intensity.